Profiel

Dr. Irene B.
Püttner is a Portfolio Manager at Credit Suisse AG.
She is a life sciences specialist with 11 years of investment track record.
She joined the Credit Suisse Group in 2008 and has managed the Credit Suisse Biotechnology Equity Fund since February 2008.
From 2001-2007 she worked as a life sciences fund manager and analyst at Bank Sarasin in Basel, Zürich and London managing HealthSar, a fund investing in biotech, pharma and medical technology companies.
In addition, she was co-manager of a fund focusing on innovation across various industries including life sciences and technology.
She dedicated her entire career to life sciences.
She got to understand the industry she is investing in from scratch: she worked during 12 years in experimental scientific research covering several therapeutic fields in academia as well as at Roche and Novartis in the USA and Switzerland, followed by eight years as business development manager with a strong deal track record at Ciba-Geigy, Novartis, Discovery Technologies and Syngenta.
Through her three decades of activities in the life science industry, she has a strong knowledge of the therapeutic areas, the companies and connections to their management.
Dr. Püttner holds a doctoral degree in natural sciences of the ETH in Zürich, Switzerland.

Eerdere bekende functies van Irene Beatrice Püttner

BedrijvenFunctieEinde
Portefeuillebeheerder-Aandelen 01-12-2016
Clariden Leu AG Portefeuillebeheerder-Aandelen 24-05-2012
Analyst-Equity 02-04-2007
Ervaring van Irene Beatrice Püttner in detail bekijken

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Irene Beatrice Püttner in detail bekijken

Connecties

100 +

Eerstegraads connecties

3

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Bedrijven in privébezit3

Finance

Clariden Leu AG

Finance

Finance

Zie bedrijfsconnecties
  1. Beurs
  2. Insiders
  3. Irene Beatrice Püttner
-40 % Aanbod van beperkte duur: onze abonnementen leiden je naar de beste beleggingen van morgen.
PROFITEER NU